MEDEXUS PHARMS INC - MEDXF STOCK NEWS

Welcome to our dedicated page for MEDEXUS PHARMS news (Ticker: MEDXF), a resource for investors and traders seeking the latest updates and insights on MEDEXUS PHARMS stock.

MEDEXUS PHARMS INC (MEDXF) is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. The company focuses on therapeutic areas such as oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Recent achievements include the approval of IXINITY for pediatric patients under 12 years of age with hemophilia B and the acceptance of treosulfan's New Drug Application for review by the FDA. MEDXF is dedicated to enhancing patient care and quality of life through its products.

09/05/2023 07:30 AM

News

Medexus Strengthens Balance Sheet with US$18 Million Commitment Under Accordion Facility

Rhea-AI Summary

Medexus Pharmaceuticals expects to fully satisfy convertible debentures in cash at maturity in October 2023 with the help of a $18 million increase in BMO's term loan commitment. The company's cash position and liquidity will be improved, allowing them to make the maturity date payment entirely in cash if they choose to do so. The weighted average interest rate on the credit facilities is 8.68%, which is lower than the previous rate of 9.02%.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.54%

Tags

08/17/2023 05:30 PM

News

Medexus Study Supports Efficacy and Safety of IXINITY in Pediatric Patients with Severe or Moderately Severe Hemophilia B

Rhea-AI Summary

Medexus Pharmaceuticals presents Phase 3/4 study data on IXINITY at NHF Bleeding Disorders Conference 2023. The study evaluated the safety and efficacy of IXINITY as a prophylactic treatment in pediatric patients with hemophilia B. Prophylaxis with IXINITY showed low annualized bleeding rates, effective control of bleeding episodes, consistent PK, and a consistent safety profile.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.26%

Tags

08/09/2023 05:30 PM

News

Medexus Announces Strong Fiscal Q1 2024 Results, Including Record Quarterly Revenue of US$31.6 Million

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.5%

Tags

08/04/2023 07:00 AM

News

Medexus to Participate in Fireside Chat at SHARE Series Event

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.71%

Tags

08/02/2023 07:00 AM

News

Medexus Schedules First Fiscal Quarter 2024 Conference Call

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

10.25%

Tags

07/12/2023 05:30 PM

News

Medexus Announces Preliminary Revenue for Fiscal Q1 2024

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

8.31%

Tags

06/21/2023 05:40 PM

News

Medexus Generates Record Revenue of Us$108.1 Million in Fiscal Year 2023

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

9.24%

Tags

06/15/2023 07:25 AM

News

FDA Accepts for Review Medexus's IXINITY Supplemental Biological License Application for Pediatric Patients

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/14/2023 05:30 PM

News

Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2023 Conference Call

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/13/2023 07:25 AM

News

Medexus Highlights Data on Trecondyv (Treosulfan) Presented at MDS 2023

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.74%

Tags

FAQ

What is the current stock price of MEDEXUS PHARMS (MEDXF)?

The current stock price of MEDEXUS PHARMS (MEDXF) is $2.24 as of December 24, 2024.

What is the market cap of MEDEXUS PHARMS (MEDXF)?

The market cap of MEDEXUS PHARMS (MEDXF) is approximately 50.8M.

What is the focus of MEDEXUS PHARMS INC?

MEDEXUS PHARMS INC focuses on therapeutic areas such as oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.

What recent achievements has MEDEXUS PHARMS INC had?

MEDEXUS PHARMS INC recently obtained FDA approval for IXINITY for pediatric patients under 12 years of age with hemophilia B and had the New Drug Application for treosulfan accepted for review.